Elios' Phase IIb Melanoma Data Are Promising, But Present Tricky Issues For Phase III Vaccine Study
Executive Summary
The biotech’s personalized vaccine shows it can reduce the risk of melanoma recurrence by 50% in the per-treatment population, but Phase III will need to demonstrate a similar benefit in an intent-to-treat population.
You may also be interested in...
Cancer Immunotherapy Reaches A Tipping Point
Now that it is clear the immune system can kill cancer, all kinds of companies are obsessed with the idea. Start-ups are tailoring business models to divergent technologies and market dynamics.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.